Our research in hematology

With BMS delivering many firsts in hematology, we are committed to the next wave of advancements for patients through our extensive portfolio and rich hematology pipeline, spanning multiple modalities, combinations and differentiated research platforms including cell therapy and targeted protein degradation.

Featured in hematology

Intended for healthcare professionals, scientific audiences and media.

Leveraging multiple treatment modalities and advanced science, we seek to address hematologic conditions in many ways. We are harnessing key biologic processes that enable us to tap into targets previously considered undruggable and design new ways to affect pathways critical to the development and persistence of blood diseases.

Explore our stories

View all

Our hematology focus areas​


A group of blood cancers that develop in the lymphatic system.

Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by early relapses and poor survival rates. Bristol Myers Squibb has played an important role in the development therapies for critical unmet needs associated with the disease.

Scientific and disease-state resources

Explore our stories

View all >      


There are more than 70 different types of lymphoma, ranging from slow growing to highly aggressive forms. Drawing on our understanding of lymphoma biology and deep experience in hematology, our portfolio spans therapies across six indications with continuing expansion and important research focus in targeted protein degradation and cell therapy.

Scientific and disease-state resources

Explore our stories

Multiple myeloma

Through our deep immunotherapy experience, we are raising standards, innovating across targets, molecular approaches and combinations to advance patient outcomes in multiple myeloma. Our diverse portfolio and pipeline encompass programs in targeted protein degradation, cell therapies, as well as other promising approaches.

Scientific and disease-state resources

Explore our stories

Myelodysplastic syndromes (MDS)

Myelodysplastic Syndromes (MDS) are diseases that can be characterized by chronic anemia and transfusion dependency. Bristol Myers Squibb has built on its longstanding experience in this area of disease by introducing unique approaches to these clinical challenges and continuing to develop these important options.

Scientific and disease-state resources


A serious myeloproliferative neoplasm, myelofibrosis disrupts the body’s production of red blood cells. Our portfolio and development pipeline include therapies that address major complications associated with the disease like enlarged spleens and moderate-to-severe anemia.

Scientific and disease-state resources

Explore our scientific resources

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.